Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare topic
No spam. Unsubscribe anytime.
Panel advances measure to improve coverage for orally administered anticancer drugs
Summary
HB 766 would expand coverage for orally administered anticancer medications; the committee adopted an amendment reinstating some present‑law cost‑sharing provisions and limiting a co‑payment change to certain high‑deductible plans, reducing the fiscal impact. The bill was reported favorable as amended.
Representative Freeman presented HB 766 on behalf of oncologists and cancer survivors, saying orally administered anticancer drugs have advanced rapidly and patients face coverage gaps. An amendment (set 4856) reinstated present law regarding cost sharing and limited co‑payment adjustment program changes to certain high‑deductible plans to reduce the fiscal note.
Committee reviewed the revised fiscal note in members’ packets and, after questions and limited debate, adopted the amendment and reported the bill favorable as amended. Supporters emphasized patient access and potential to reduce out‑of‑pocket burdens for cancer patients.
What’s next: HB 766 was reported favorable as amended and will move forward in the legislative process.
